Standard Biotools Company Insiders
LAB Stock | USD 1.23 0.02 1.60% |
About 78 percent of all Standard Biotools' insiders are aggressively buying. The analysis of insiders' sentiment of trading Standard Biotools stock suggests that quite a large number of insiders are very bullish at this time. Standard Biotools employs about 814 people. The company is managed by 22 executives with a total tenure of roughly 1900 years, averaging almost 86.0 years of service per executive, having 37.0 employees per reported executive.
Insider Sentiment 78
Aggressively Buying
Selling | Buying |
Latest Trades
2025-05-23 | Hanjoon Alex Kim | Disposed 1428 @ 0.94 | View | ||
2025-05-22 | Sean Mackay | Disposed 12536 @ 1 | View | ||
2025-05-21 | Sean Mackay | Disposed 12838 @ 1.03 | View | ||
2025-02-28 | Casdin Partners Master Fund, L | Acquired 4820959 @ 1.06 | View | ||
2024-08-26 | Casdin Partners Master Fund, L | Acquired 150000 @ 2.15 | View | ||
2024-08-23 | Casdin Partners Master Fund, L | Acquired 292100 @ 2.13 | View | ||
2024-08-21 | Casdin Partners Master Fund, L | Acquired 500000 @ 1.9 | View | ||
2024-08-19 | Casdin Partners Master Fund, L | Acquired 250000 @ 1.85 | View | ||
2024-08-14 | Casdin Partners Master Fund, L | Acquired 1200000 @ 1.59 | View | ||
2024-08-12 | Casdin Partners Master Fund, L | Acquired 500000 @ 1.64 | View | ||
2024-08-09 | Casdin Partners Master Fund, L | Acquired 525408 @ 1.61 | View | ||
2024-08-07 | Casdin Partners Master Fund, L | Acquired 500000 @ 1.57 | View | ||
2024-08-05 | Casdin Partners Master Fund, L | Acquired 200000 @ 1.58 | View | ||
2024-08-02 | Casdin Partners Master Fund, L | Acquired 1000000 @ 1.63 | View |
Monitoring Standard Biotools' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. Standard Biotools Management Team Effectiveness
The company has Return on Asset of (0.1163) % which means that on every $100 spent on assets, it lost $0.1163. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2573) %, meaning that it generated no profit with money invested by stockholders. Standard Biotools' management efficiency ratios could be used to measure how well Standard Biotools manages its routine affairs as well as how well it operates its assets and liabilities. As of July 20, 2025, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.34. At present, Standard Biotools' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 26.1 M, whereas Non Current Assets Total are forecasted to decline to about 131.6 M.The current year's Common Stock Shares Outstanding is expected to grow to about 370.9 M, whereas Net Loss is projected to grow to (162.5 M).
Standard Biotools Workforce Comparison
Standard Biotools is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 28,046. Standard Biotools holds roughly 814 in number of employees claiming about 2.9% of equities under Health Care industry.
Standard Biotools Profit Margins
The company has Net Profit Margin of (0.78) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.29) %, which entails that for every $100 of revenue, it lost $0.29.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.63 | 0.4831 |
|
|
Standard Biotools Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Standard Biotools insiders, such as employees or executives, is commonly permitted as long as it does not rely on Standard Biotools' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Standard Biotools insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Witney Frank over three weeks ago Acquisition by Witney Frank of 125660 shares of Standard Biotools at 1.05 subject to Rule 16b-3 | ||
Cox Troy over a month ago Acquisition by Cox Troy of 72213 shares of Standard Biotools at 1.77 subject to Rule 16b-3 | ||
Michael Egholm over a month ago Disposition of 5473 shares by Michael Egholm of Standard Biotools at 0.941 subject to Rule 16b-3 | ||
Sean Mackay over a month ago Disposition of 12536 shares by Sean Mackay of Standard Biotools at 1.002 subject to Rule 16b-3 | ||
Hanjoon Kim over a month ago Disposition of 1407 shares by Hanjoon Kim of Standard Biotools at 1.03 subject to Rule 16b-3 | ||
Hanjoon Kim over two months ago Disposition of 6364 shares by Hanjoon Kim of Standard Biotools at 1.05 subject to Rule 16b-3 | ||
Hanjoon Kim over three months ago Disposition of 70183 shares by Hanjoon Kim of Standard Biotools subject to Rule 16b-3 | ||
Michael Egholm over three months ago Acquisition by Michael Egholm of 1188333 shares of Standard Biotools subject to Rule 16b-3 |
Standard Biotools Notable Stakeholders
A Standard Biotools stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Standard Biotools often face trade-offs trying to please all of them. Standard Biotools' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Standard Biotools' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Egholm | CEO President | Profile | |
Sean Mackay | Chief VP | Profile | |
Jonathan Mickelsen | VP Officer | Profile | |
Jeffrey Black | Chief Officer | Profile | |
Shane Bowen | Chief Officer | Profile | |
Elizabeth Jensen | Chief Officer | Profile | |
Mark Spearman | Sr Communications | Profile | |
Mike Musgnug | Senior Officer | Profile | |
John Graziano | Vice Relations | Profile | |
Dr Dphil | CoFounder Board | Profile | |
Peter DeNardo | Investor Relations | Profile | |
Stephen Linthwaite | Advisor | Profile | |
BS MB | Chief Officer | Profile | |
Hanjoon Kim | Chief Officer | Profile | |
David Holmes | Investor Relations | Profile | |
Rafael AguirreSacasa | Acting Counsel | Profile | |
Adam Taich | Chief Officer | Profile | |
David King | VP RD | Profile | |
Andrew Quong | Chief Officer | Profile | |
Jeremy Davis | Chief Officer | Profile | |
Vikram Jog | Chief Officer | Profile | |
Angela Peters | Chief Officer | Profile |
About Standard Biotools Management Performance
The success or failure of an entity such as Standard Biotools often depends on how effective the management is. Standard Biotools management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Standard management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Standard management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.29) | (0.31) | |
Return On Capital Employed | (0.32) | (0.34) | |
Return On Assets | (0.23) | (0.24) | |
Return On Equity | (0.29) | (0.31) |
Please note, the presentation of Standard Biotools' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Standard Biotools' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Standard Biotools' management manipulating its earnings.
Standard Biotools Workforce Analysis
Traditionally, organizations such as Standard Biotools use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Standard Biotools within its industry.Standard Biotools Manpower Efficiency
Return on Standard Biotools Manpower
Revenue Per Employee | 214.3K | |
Revenue Per Executive | 7.9M | |
Net Loss Per Employee | 170.6K | |
Net Loss Per Executive | 6.3M | |
Working Capital Per Employee | 380.8K | |
Working Capital Per Executive | 14.1M |
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Transaction History View history of all your transactions and understand their impact on performance |